ADDYI (flibanserin)
HSDD AGENTS-MIXED SEROTONIN AGONIST/ANTAGONISTS · PREMENOPAUSAL ACQUIRED HYPOACTIVE SEXUAL DESIRE DISORDER
SPROUT PHARMACE
Drug class
Hypoactive Sexual Desire Disorder (HSDD) Treatment Agents
Hypoactive Sexual Desire Disorder (HSDD) treatment agents are a pharmacotherapeutic category of central nervous system modulators formulated to address acquired, generalized hypoactive sexual desire disorder in premenopausal women. Read more about Hypoactive Sexual Desire Disorder (HSDD) Treatment Agents
2 drugs in this class 2 manufacturers
Drugs in Hypoactive Sexual Desire Disorder (HSDD) Treatment Agents
VYLEESI (bremelanotide acetate)
HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT AGENTS · PREMENOPAUSAL ACQUIRED HYPOACTIVE SEXUAL DESIRE DISORDER
Cosette Pharmaceuticals
Filter & compare in the drug finder →
Opens the drug finder with Hypoactive Sexual Desire Disorder (HSDD) Treatment Agents preselected. Add indication or manufacturer filters there.
Hypoactive Sexual Desire Disorder (HSDD) treatment agents are a pharmacotherapeutic category of central nervous system modulators formulated to address acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Rather than acting via peripheral vascular mechanisms, these medications modulate key central neurochemical pathways involved in sexual motivation, balance, and inhibition, primarily functioning as multifunctional serotonin receptor agonists/antagonists or melanocortin receptor agonists.
Their primary therapeutic role is to restore baseline sexual interest and reduce the marked personal distress or interpersonal difficulty associated with persistent low libido.
-
fda.gov
Hypoactive Sexual Desire Disorder (HSDD) treatment agents are a pharmacotherapeutic category of central nervous system modulators formulated to address acquired, generalized hypoactive sexual desire disorder in premenopausal women Rather than acting via peripheral vascular mechanisms, these medications modulate key central neurochemical pathways involved in sexual motivation, balance, and inhibition, primarily functioning as multifunctional serotonin receptor agonists/antagonists or melanocortin...
-
fda.gov
Hypoactive Sexual Desire Disorder (HSDD) treatment agents are a pharmacotherapeutic category of central nervous system modulators formulated to address acquired, generalized hypoactive sexual desire disorder in premenopausal women Their primary therapeutic role is to restore baseline sexual interest and reduce the marked personal distress or interpersonal difficulty associated with persistent low libido
-
nih.gov
Rather than acting via peripheral vascular mechanisms, these medications modulate key central neurochemical pathways involved in sexual motivation, balance, and inhibition, primarily functioning as multifunctional serotonin receptor agonists/antagonists or melanocortin receptor agonists
-
fda.gov
Their primary therapeutic role is to restore baseline sexual interest and reduce the marked personal distress or interpersonal difficulty associated with persistent low libido
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.